GB0919431D0
(en)
*
|
2009-11-05 |
2009-12-23 |
Glaxosmithkline Llc |
Novel compounds
|
EP2569434B1
(en)
|
2010-05-14 |
2019-09-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating leukemia and related disorders
|
HUE031073T2
(en)
|
2010-05-14 |
2017-06-28 |
Dana Farber Cancer Inst Inc |
Thieno triazolo-diazepine compounds for the treatment of neoplasia
|
US9301962B2
(en)
|
2010-05-14 |
2016-04-05 |
Baylor College Of Medicine |
Male contraceptive compositions and methods of use
|
AR084070A1
(es)
|
2010-12-02 |
2013-04-17 |
Constellation Pharmaceuticals Inc |
Inhibidores del bromodominio y usos de los mismos
|
US9249161B2
(en)
|
2010-12-02 |
2016-02-02 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
GB201106750D0
(en)
*
|
2011-04-21 |
2011-06-01 |
Glaxosmithkline Llc |
Novel compounds
|
GB201106743D0
(en)
*
|
2011-04-21 |
2011-06-01 |
Glaxosmithkline Llc |
Novel compounds
|
GB201107325D0
(en)
|
2011-05-04 |
2011-06-15 |
Glaxosmithkline Llc |
Novel compounds
|
US9422292B2
(en)
|
2011-05-04 |
2016-08-23 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
EP2721031B1
(en)
|
2011-06-17 |
2016-01-20 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
GB201114103D0
(en)
*
|
2011-08-17 |
2011-09-28 |
Glaxosmithkline Llc |
Novel compounds
|
WO2013027168A1
(en)
|
2011-08-22 |
2013-02-28 |
Pfizer Inc. |
Novel heterocyclic compounds as bromodomain inhibitors
|
WO2013033269A1
(en)
*
|
2011-08-29 |
2013-03-07 |
Coferon, Inc. |
Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
|
WO2013097052A1
(en)
*
|
2011-12-30 |
2013-07-04 |
Abbott Laboratories |
Bromodomain inhibitors
|
MX2014012635A
(es)
|
2012-04-20 |
2015-05-15 |
Abbvie Inc |
Derivados de isoindolona.
|
TWI602820B
(zh)
|
2012-06-06 |
2017-10-21 |
星宿藥物公司 |
溴域抑制劑及其用途
|
EP2864336B1
(en)
|
2012-06-06 |
2016-11-23 |
Constellation Pharmaceuticals, Inc. |
Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof
|
EP2858982A4
(en)
|
2012-06-12 |
2015-11-11 |
Abbvie Inc |
PYRIDINONE AND PYRIDAZINONE DERIVATIVES
|
US9763956B2
(en)
|
2012-06-19 |
2017-09-19 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
|
KR20150096794A
(ko)
|
2012-12-21 |
2015-08-25 |
제니쓰 에피제네틱스 코포레이션 |
브로모도메인 저해제로서의 신규한 헤테로사이클릭 화합물
|
AU2014249192B2
(en)
|
2013-03-11 |
2017-12-21 |
The Regents Of The University Of Michigan |
BET bromodomain inhibitors and therapeutic methods using the same
|
EP2970127B1
(en)
|
2013-03-14 |
2018-10-24 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
|
US9714946B2
(en)
|
2013-03-14 |
2017-07-25 |
Dana-Farber Cancer Institute, Inc. |
Bromodomain binding reagents and uses thereof
|
EP2968360B1
(en)
|
2013-03-14 |
2021-01-20 |
ConverGene LLC |
Quinolinone derivatives for the inhibition of bromodomain-containing proteins
|
ES2654362T3
(es)
|
2013-03-14 |
2018-02-13 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Furopiridinas como inhibidores de bromodominio
|
EP2970282B1
(en)
|
2013-03-15 |
2019-08-21 |
Incyte Holdings Corporation |
Tricyclic heterocycles as bet protein inhibitors
|
CA2901083A1
(en)
|
2013-04-26 |
2014-10-30 |
Beigene, Ltd. |
Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
|
CN109939113B
(zh)
*
|
2013-06-21 |
2022-02-15 |
恒翼生物医药科技(上海)有限公司 |
双环溴结构域抑制剂
|
US9636328B2
(en)
|
2013-06-21 |
2017-05-02 |
Zenith Epigenetics Ltd. |
Substituted bicyclic compounds as bromodomain inhibitors
|
CN105518007A
(zh)
*
|
2013-06-28 |
2016-04-20 |
艾伯维公司 |
布罗莫结构域抑制剂
|
AR096758A1
(es)
*
|
2013-06-28 |
2016-02-03 |
Abbvie Inc |
Inhibidores cristalinos de bromodominios
|
EP3019502B1
(en)
|
2013-07-08 |
2017-05-17 |
Incyte Holdings Corporation |
Tricyclic heterocycles as bet protein inhibitors
|
KR20160034379A
(ko)
|
2013-07-25 |
2016-03-29 |
다나-파버 캔서 인스티튜트 인크. |
전사 인자의 억제제 및 그의 용도
|
CA2919948C
(en)
|
2013-07-31 |
2020-07-21 |
Zenith Epigenetics Corp. |
Novel quinazolinones as bromodomain inhibitors
|
PL3640241T3
(pl)
*
|
2013-10-18 |
2022-12-05 |
Celgene Quanticel Research, Inc. |
Inhibitory bromodomeny
|
WO2015070020A2
(en)
|
2013-11-08 |
2015-05-14 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
|
CN106029076B
(zh)
|
2013-11-18 |
2019-06-07 |
福马疗法公司 |
作为bet溴域抑制剂的苯并哌嗪组合物
|
MX370535B
(es)
*
|
2013-11-18 |
2019-12-17 |
Forma Therapeutics Inc |
Compuestos de tetrahidroquinolina como inhibidores del bromodominio extra terminal y bromo (bet) y el uso de los mismos en el tratamiento de cáncer.
|
US9108953B2
(en)
*
|
2013-11-26 |
2015-08-18 |
Gilead Sciences, Inc. |
Quinoline derivatives as bromodomain inhibitors
|
US9399640B2
(en)
|
2013-11-26 |
2016-07-26 |
Incyte Corporation |
Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
|
WO2015081189A1
(en)
|
2013-11-26 |
2015-06-04 |
Incyte Corporation |
Bicyclic heterocycles as bet protein inhibitors
|
US9309246B2
(en)
|
2013-12-19 |
2016-04-12 |
Incyte Corporation |
Tricyclic heterocycles as BET protein inhibitors
|
BR112016015311B1
(pt)
|
2014-01-09 |
2023-01-24 |
Orion Corporation |
Compostos derivados heterocíclicos bicíclicos, composição farmacêutica que compreende os mesmos e uso dos ditos compostos para tratar uma doença associada com bromodomínio
|
EA038715B1
(ru)
*
|
2014-01-24 |
2021-10-08 |
Селджен Квонтисел Рисёрч, Инк. |
Ингибиторы бромодомена
|
WO2015117083A1
(en)
|
2014-01-31 |
2015-08-06 |
Dana-Farber Cancer Institute, Inc. |
Diazepane derivatives and uses thereof
|
CA2936865A1
(en)
|
2014-01-31 |
2015-08-06 |
Dana-Farber Cancer Institute, Inc. |
Diaminopyrimidine benzenesulfone derivatives and uses thereof
|
EP3099693A4
(en)
|
2014-01-31 |
2017-08-16 |
Dana-Farber Cancer Institute, Inc. |
Uses of diazepane derivatives
|
AU2015222805B2
(en)
|
2014-02-28 |
2020-05-21 |
Tensha Therapeutics, Inc. |
Treatment of conditions associated with hyperinsulinaemia
|
JP2017511801A
(ja)
|
2014-02-28 |
2017-04-27 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
BETブロモドメイン阻害剤としての9H−ピリミド[4,5−b]インドールおよび関連類似体
|
MY180775A
(en)
|
2014-04-23 |
2020-12-09 |
Incyte Corp |
1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
|
EP3157928B1
(en)
|
2014-06-20 |
2019-02-13 |
Constellation Pharmaceuticals, Inc. |
Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide
|
CA2955077A1
(en)
|
2014-08-08 |
2016-02-11 |
Dana-Farber Cancer Institute, Inc. |
Dihydropteridinone derivatives and uses thereof
|
CN106715437A
(zh)
|
2014-08-08 |
2017-05-24 |
达纳-法伯癌症研究所股份有限公司 |
二氮杂环庚烷衍生物及其用途
|
DK3191476T3
(en)
*
|
2014-09-12 |
2019-01-14 |
Glaxosmithkline Ip No 2 Ltd |
TETRAHYDROQUINOLINE DERIVATIVES AS BROOM DOMAIN INHIBITORS.
|
JP6599979B2
(ja)
|
2014-09-15 |
2019-10-30 |
インサイト・コーポレイション |
Betタンパク質阻害剤として用いるための三環式複素環化合物
|
BR112017008714A2
(pt)
|
2014-10-27 |
2017-12-19 |
Tensha Therapeutics Inc |
inibidores de bromodomínio
|
EP3227280B1
(en)
|
2014-12-01 |
2019-04-24 |
Zenith Epigenetics Ltd. |
Substituted pyridines as bromodomain inhibitors
|
WO2016087936A1
(en)
|
2014-12-01 |
2016-06-09 |
Zenith Epigenetics Corp. |
Substituted pyridinones as bromodomain inhibitors
|
CA2966449A1
(en)
|
2014-12-11 |
2016-06-16 |
Zenith Epigenetics Ltd. |
Substituted heterocycles as bromodomain inhibitors
|
EP3233846A4
(en)
|
2014-12-17 |
2018-07-18 |
Zenith Epigenetics Ltd. |
Inhibitors of bromodomains
|
WO2016138332A1
(en)
|
2015-02-27 |
2016-09-01 |
The Regents Of The University Of Michigan |
9h-pyrimido [4,5-b] indoles as bet bromodomain inhibitors
|
GB201503720D0
(en)
|
2015-03-05 |
2015-04-22 |
Glaxosmithkline Ip No 2 Ltd |
Chemical compound
|
GB201504694D0
(en)
|
2015-03-19 |
2015-05-06 |
Glaxosmithkline Ip Dev Ltd |
Covalent conjugates
|
GB201504689D0
(en)
|
2015-03-19 |
2015-05-06 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
US10702517B2
(en)
|
2015-04-22 |
2020-07-07 |
Celgene Quanticel Research, Inc. |
Bromodomain inhibitor
|
TW201642860A
(zh)
*
|
2015-04-22 |
2016-12-16 |
塞爾基因定量細胞研究公司 |
布羅莫結構域抑制劑
|
WO2016196065A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Methods and compositions for assessing responsiveness of cancers to bet inhibitors
|
AU2016276963C1
(en)
|
2015-06-12 |
2021-08-05 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
WO2016203335A1
(en)
|
2015-06-18 |
2016-12-22 |
Pfizer Inc. |
Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
|
MA42249A
(fr)
|
2015-06-26 |
2018-05-02 |
Tensha Therapeutics Inc |
Traitement de carcinome de la ligne médiane nut
|
WO2017027571A1
(en)
|
2015-08-10 |
2017-02-16 |
Dana-Farber Cancer Institute, Inc. |
Mechanism of resistance to bet bromodomain inhibitors
|
AU2016315360B2
(en)
|
2015-09-02 |
2019-09-12 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Pyridinone dicarboxamide for use as bromodomain inhibitors
|
WO2017044849A1
(en)
|
2015-09-11 |
2017-03-16 |
Dana-Farber Cancer Institute, Inc. |
Cyano thienotriazolodiazepines and uses thereof
|
PE20181086A1
(es)
|
2015-09-11 |
2018-07-05 |
Dana Farber Cancer Inst Inc |
Acetamida tienotrizolodiazepinas y usos de las mismas
|
US10370356B2
(en)
|
2015-09-22 |
2019-08-06 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Pyridinone dicarboxamide for use as bromodomain inhibitors
|
EP3359531B1
(en)
|
2015-10-05 |
2020-08-19 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
2-oxo-1,2-dihydropyridine-3,5-dicarboxamide compounds as bromodomain inhibitors
|
TW201722966A
(zh)
|
2015-10-29 |
2017-07-01 |
英塞特公司 |
Bet蛋白質抑制劑之非晶固體形式
|
SG10201913450PA
(en)
|
2015-11-25 |
2020-03-30 |
Dana Farber Cancer Inst Inc |
Bivalent bromodomain inhibitors and uses thereof
|
CN109071562B
(zh)
|
2016-02-15 |
2022-03-22 |
密执安大学评议会 |
作为bet溴结构域抑制剂的稠合1,4-氧氮杂䓬和相关类似物
|
US10759808B2
(en)
|
2016-04-06 |
2020-09-01 |
The Regents Of The University Of Michigan |
Monofunctional intermediates for ligand-dependent target protein degradation
|
SG11201808728QA
(en)
|
2016-04-06 |
2018-11-29 |
Univ Michigan Regents |
Mdm2 protein degraders
|
AU2017245641A1
(en)
|
2016-04-07 |
2018-09-13 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Pyridyl derivatives as bromodomain inhibitors
|
BR112018070514A2
(pt)
|
2016-04-07 |
2019-01-29 |
Glaxosmithkline Ip No 2 Ltd |
composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
|
US10633386B2
(en)
|
2016-04-12 |
2020-04-28 |
The Regents Of The University Of Michigan |
BET protein degraders
|
RU2741808C2
(ru)
|
2016-04-15 |
2021-01-28 |
Эббви Инк. |
Ингибиторы бромодомена
|
EP4067347B1
(en)
*
|
2016-05-24 |
2024-06-19 |
Genentech, Inc. |
Heterocyclic inhibitors of cbp/ep300 for the treatment of cancer
|
BR112018073524A2
(pt)
|
2016-05-24 |
2019-05-28 |
Glaxosmithkline Ip No 2 Ltd |
composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição.
|
EP4234554A3
(en)
|
2016-06-20 |
2023-12-27 |
Incyte Corporation |
Crystalline solid forms of a bet inhibitor
|
GB201614940D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Chemical compounds
|
GB201614934D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Chemical compounds
|
GB201614939D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Ip Dev Ltd |
Crystalline hydrate
|
WO2018052949A1
(en)
|
2016-09-13 |
2018-03-22 |
The Regents Of The University Of Michigan |
Fused 1,4-diazepines as bet protein degraders
|
US11466028B2
(en)
|
2016-09-13 |
2022-10-11 |
The Regents Of The University Of Michigan |
Fused 1,4-oxazepines as BET protein degraders
|
JP7129973B2
(ja)
*
|
2016-10-20 |
2022-09-02 |
セルジーン クオンティセル リサーチ,インク. |
ブロモドメイン阻害剤
|
US11028051B2
(en)
*
|
2016-12-13 |
2021-06-08 |
St. Jude Children's Research Hospital |
Tetrahydroquinoline-based bromodomain inhibitors
|
WO2018144789A1
(en)
|
2017-02-03 |
2018-08-09 |
The Regents Of The University Of Michigan |
Fused 1,4-diazepines as bet bromodomain inhibitors
|
GB201716374D0
(en)
*
|
2017-10-06 |
2017-11-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
JOP20190192A1
(ar)
*
|
2017-03-01 |
2019-08-08 |
Glaxosmithkline Ip No 2 Ltd |
مشتقات بيرازول بوصفها مثبطات برومودومين
|
GB201703282D0
(en)
|
2017-03-01 |
2017-04-12 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
WO2019055444A1
(en)
|
2017-09-13 |
2019-03-21 |
The Regents Of The University Of Michigan |
DEGRADATION AGENTS OF BROMODOMAIN BET PROTEIN WITH CLEAR BINDERS
|
GB201716392D0
(en)
|
2017-10-06 |
2017-11-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
GB201716369D0
(en)
|
2017-10-06 |
2017-11-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
GB201814167D0
(en)
|
2018-08-31 |
2018-10-17 |
Glaxosmithkline Ip No 2 Ltd |
Compounds
|
TWI816880B
(zh)
*
|
2018-09-13 |
2023-10-01 |
大陸商恒翼生物醫藥(上海)股份有限公司 |
治療前列腺癌之組合療法
|
WO2021175432A1
(en)
|
2020-03-04 |
2021-09-10 |
Boehringer Ingelheim International Gmbh |
Method for administration of an anti cancer agent
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
WO2023041744A1
(en)
|
2021-09-17 |
2023-03-23 |
Institut Curie |
Bet inhibitors for treating pab1 deficient cancer
|
WO2023205251A1
(en)
|
2022-04-19 |
2023-10-26 |
Nuevolution A/S |
Compounds active towards bromodomains
|